Harrow expands patient access to eyecare medications with price reductions and GoodRx partnership

Author(s):

Sydney M Crago

Key Takeaways

Harrow's initiative includes price reductions for ophthalmic products to address cost barriers and improve patient access.
A strategic partnership with GoodRx offers a cash-pay alternative, providing discounted pricing for select Harrow products.
The program aims to help patients lacking adequate insurance coverage access critical eyecare medications.
Harrow's CEO highlights the dual benefit of enhancing patient access to treatments and delivering shareholder value.

(Image Credit: AdobeStock/amazing studio)

Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products. This includes a program of targeted price reductions for several Harrow products and a strategic partnership with GoodRx.

A component of Harrow’s Access and Affordability Program is reducing the prices of several widely used eyecare products as a method of addressing cost barriers that limit patient access. The program began with price reductions for 2 of the company’s products, VIGAMOX and MAXIDEX, with the analysis of additional products underway.¹

Harrow’s new partnership with GoodRx will provide a cash-pay alternative for the purchase of select Harrow products, including FLAREX, ILEVRO, MAXIDEX, TOBRADEXST, VEVYE, VIGAMOX, and ZERVIATE. The GoodRx platform offers an alternative to traditional insurance allowing patients discounted pricing. This partnership may address the financial needs of those patients who may not have adequate insurance coverage for the eyecare medications they need.¹

Mark L. Baum, Chairman and Chief Executive Officer of Harrow, spoke to the mission behind these decisions and the benefit these programs may provide to patients, saying, “Our company was founded on a mission to help patients manage and preserve their sight by providing access to innovative and affordable medicines, and these initiatives are a significant step in advancing that mission. Patients often tell us that insurance co-payments can make their medications cost-prohibitive. By reducing prices and providing new access points, we’re creating a win-win: helping patients access critical sight-saving treatments while simultaneously delivering improved value to Harrow’s shareholders.”¹

In the press release¹, the company noted that patients can search for participating pharmacies and access discounts directly through the GoodRx website or mobile app to take advantage of this partnership.

Reference:

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products. Harrow, Inc. November 13, 2024. Accessed November 19, 2024. https://www.businesswire.com/news/home/20241113864368/en/Harrow-Launches-Access-and-Affordability-Program-with-Price-Reductions-for-Branded-Products